AMENDED AND RESTATED SUBLICENSE AGREEMENTSublicense Agreement • August 12th, 2009 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
THIS AMENDED AND RESTATED SUBLICENSE AGREEMENT (the “Agreement”), effective this 8th day of June, 2009 (the “Effective Date”), by and between KERYX BIOPHARMACEUTICALS, INC., with offices at 750 Lexington Avenue, 20th Floor, New York, NY 10022, U.S.A. (“Keryx” or “Sublicensor”) and JAPAN TOBACCO INC., with offices at JT Building, 2-1, Toranomon 2-Chome, Minato-ku, Tokyo 105-8422, Japan (“JT”) and TORII PHARMACEUTICAL CO., LTD., with offices at Torii Nihonbashi Bldg., 4-1, Nihonbashi-Honcho 3-chome, Chuo-ku, Tokyo 103-8439, Japan (“TORII”) (JT and TORII collectively referred to herein as “Sublicensee”);
SETTLEMENT AGREEMENT AND GENERAL RELEASESettlement Agreement • August 12th, 2009 • Keryx Biopharmaceuticals Inc • Pharmaceutical preparations • New York
This Settlement Agreement and General Release (the “Agreement”) is made and entered into between Keryx Biopharmaceuticals, Inc. (hereinafter “Keryx”) on the one hand and Alfa Wassermann S.p.A. (hereinafter “Alfa”) on the other hand (Keryx and Alfa are collectively referred to as the “Parties”).
